By Owen Tucker-Smith
Shares for Charles River Laboratories slipped after the company said it expects revenue to decline in 2025.
Shares of the Massachusetts-based pharmaceutical company were recently down 6% to $178.50 in morning trading. The stock is about 35% below its 52-week peak of $275.
The company said there is a slowdown in its Discovery and Safety Assessment business, as spending from biopharma clients tightens globally due to restructuring programs and reprioritization efforts.
Charles River also said one of its clients is terminating its commercial agreement with the company, further weighing on revenue.
While the company said it will try to save money through restructuring initiatives, those efforts will not be enough to completely offset the anticipated revenue drop. Charles River expects its adjusted operating margin to fall below its expected 2024 level.
The company is scheduled to present its strategic focus, business developments and trends at the JPMorgan Healthcare Conference later Tuesday. It plans to report earnings in mid-February.
Write to Owen Tucker-Smith at owen.tucker-smith@wsj.com
(END) Dow Jones Newswires
January 14, 2025 11:23 ET (16:23 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。